Solid BiosciencesSLDB
SLDB
About: Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
Employees: 100
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
240% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 15
187% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 15
101% more capital invested
Capital invested by funds: $145M [Q4 2024] → $292M (+$146M) [Q1 2025]
39% more funds holding
Funds holding: 90 [Q4 2024] → 125 (+35) [Q1 2025]
10.83% more ownership
Funds ownership: 90.92% [Q4 2024] → 101.75% (+10.83%) [Q1 2025]
0% more call options, than puts
Call options by funds: $714K | Put options by funds: $714K
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$10
122%
upside
Avg. target
$15
233%
upside
High target
$17
277%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
JMP Securities Silvan Tuerkcan | 233%upside $15 | Market Outperform Reiterated | 6 Jun 2025 |
Cantor Fitzgerald Kristen Kluska | 255%upside $16 | Overweight Assumed | 22 May 2025 |
Chardan Capital Geulah Livshits | 233%upside $15 | Buy Maintained | 19 May 2025 |
Piper Sandler Biren Amin | 277%upside $17 | Overweight Maintained | 16 May 2025 |
Wedbush Laura Chico | 277%upside $17 | Outperform Maintained | 16 May 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 34,550 restricted stock units (“RSUs”) to two newly hired employees.
Neutral
GlobeNewsWire
2 weeks ago
Solid Biosciences to Participate at the Jefferies Global Healthcare Conference
CHARLESTOWN, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, announced that Bo Cumbo, President and CEO, and Gabriel Brooks, M.D.
Neutral
GlobeNewsWire
1 month ago
Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates
- Duchenne (SGT-003) : Participant dosing ongoing in the Phase 1/2 INSPIRE DUCHENNE trial; Solid on track to discuss accelerated pathways with U.S. FDA later in 2025 - - FA (SGT-212): Dosing of first participant anticipated in the second half of 2025 - - CPVT (SGT-501): FDA IND on track for submission first half of 2025 - - Cash: Company ended first quarter 2025 with $306.9 million in cash, cash equivalents, investments and available-for-sale securities; Solid has anticipated cash runway into the first half of 2027 - CHARLESTOWN, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision, next generation, genetic medicines for neuromuscular and cardiac diseases, today reported financial results for the first quarter ended March 31, 2025, and provided a business update.
Neutral
GlobeNewsWire
1 month ago
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 81,000 restricted stock units (“RSUs”) to seven newly hired employees.
Neutral
GlobeNewsWire
1 month ago
Solid Biosciences to Participate at The Citizens Life Sciences Conference
CHARLESTOWN, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, announced that Bo Cumbo, President and CEO, will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7, at 12:30 pm ET.
Neutral
GlobeNewsWire
1 month ago
Solid Biosciences to Present at the American Society of Gene and Cell Therapy's 28th Annual Meeting
CHARLESTOWN, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy product candidate intended for the treatment of Duchenne muscular dystrophy (Duchenne), at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), from May 13-17, 2025, in New Orleans, LA.
Positive
Seeking Alpha
2 months ago
Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space
Solid Biosciences is repositioning itself in a scrutinized space with promising early-stage trial results for its lead candidate, SGT-003. Recent events involving Sarepta Therapeutics have unfairly impacted Solid's stock price, creating a potential recovery opportunity if Sarepta clarifies the isolated nature of the patient's death. Solid's pipeline includes SGT-003 for DMD, SGT-212 for Friedreich's ataxia, and SGT-501 for CPVT, with promising early data and no serious adverse effects.
Positive
MarketBeat
2 months ago
Can Solid Biosciences Challenge Sarepta in the DMD Market?
When it comes to treating Duchenne muscular dystrophy (DMD), big news recently surfaced. DMD is a muscle disease.
Neutral
GlobeNewsWire
2 months ago
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 43,374 restricted stock units (“RSUs”) to three newly hired employees.
Negative
New York Post
2 months ago
Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul
Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official was forced to resign, the most high-profile exit at the regulator as the Trump administration undertakes an overhaul of federal health agencies.
Charts implemented using Lightweight Charts™